Byron C.  Scott net worth and biography

Byron Scott Biography and Net Worth

Director of Accuray
Byron C. Scott has served as a member of our Board since February 2021.  Dr. Scott has served as Adjunct Faculty at the University of Massachusetts, Amherst, Isenberg School of Management since 2016 and Adjunct Faculty at Jefferson University, College of Population Health since 2019 where he teaches healthcare quality, patient safety, and performance improvement.  Dr. Scott served as Deputy Chief Health Officer at IBM Watson Health from 2017 to 2020, where he served as a consultant helping healthcare organizations align strategies and improve performance, along with supporting sales, marketing, and thought leadership.  Dr. Scott served at Truven Health Analytics from 2014 to 2017, most recently as Associate Chief Medical Officer from 2015 to 2017, prior to its acquisition by IBM in 2016.  Dr. Scott previously served at EmCare, a hospital-based physician practice management company that was part of Envision Healthcare, from 1995 to 2013, where he held positions of increasing responsibility, including most recently as Executive Vice President of the West Division from 2011 to 2013.

Dr. Scott is board certified in emergency medicine and previously practiced medicine for over 25 years. He serves as a member of the Board of Directors of Direct Relief and Board Trustee at Rady Children’s Hospital-San Diego.  Dr. Scott holds a B.S. in Psychobiology from the University of California, Los Angeles, a M.D. from the University of California, San Diego, and a M.B.A. from the University of Massachusetts, Amherst, Isenberg School of Management. He is Directorship Certified by the National Association for Corporate Directors (NACD) and a CERT Cybersecurity Oversight Certification issued by Carnegie Mellon University and NACD.

How do I contact Byron C. Scott?

The corporate mailing address for Dr. Scott and other Accuray executives is 1310 CHESAPEAKE TERRACE, SUNNYVALE CA, 94089. Accuray can also be reached via phone at (408) 716-4600 and via email at [email protected]. Learn More on Byron C. Scott's contact information.

Has Byron C. Scott been buying or selling shares of Accuray?

Byron C. Scott has not been actively trading shares of Accuray during the last quarter. Most recently, on Monday, November 8th, Byron C. Scott bought 9,000 shares of Accuray stock. The stock was acquired at an average cost of $5.45 per share, with a total value of $49,050.00. Learn More on Byron C. Scott's trading history.

Who are Accuray's active insiders?

Accuray's insider roster includes Jesse Chew (SVP), Brandon Green (CFO), Michael Hoge (VP), Joshua Levine (CEO), Byron Scott (Director), Patrick Spine (SVP), Joseph Whitters (Director), and Suzanne Winter (President). Learn More on Accuray's active insiders.

Are insiders buying or selling shares of Accuray?

In the last year, Accuray insiders bought shares 1 times. They purchased a total of 50,000 shares worth more than $77,000.00. In the last year, insiders at the medical equipment provider sold shares 14 times. They sold a total of 233,262 shares worth more than $614,014.20. The most recent insider tranaction occured on June, 4th when CFO Ali Pervaiz sold 2,701 shares worth more than $4,591.70. Insiders at Accuray own 3.8% of the company. Learn More about insider trades at Accuray.

Information on this page was last updated on 6/4/2024.

Byron C. Scott Insider Trading History at Accuray

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
11/8/2021Buy9,000$5.45$49,050.00View SEC Filing Icon  
8/18/2021Buy10,000$3.65$36,500.00View SEC Filing Icon  
See Full Table

Byron C. Scott Buying and Selling Activity at Accuray

This chart shows Byron C Scott's buying and selling at Accuray by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Accuray Company Overview

Accuray logo
Accuray Incorporated designs, develops, manufactures, and sells radiosurgery and radiation therapy systems for the treatment of tumors in the United States, Canada, Latin America, Australia, New Zealand, Europe, the Middle East, India, Africa, Japan, China, and rest of the Asia Pacific region. It offers the CyberKnife System, a robotic stereotactic radiosurgery and stereotactic body radiation therapy system used for the treatment of primary and metastatic tumors outside the brain, including tumors on or near the spine and in the breast, kidney, liver, lung, pancreas, and prostate. The company also provides the TomoTherapy System, including the Radixact System, which allows for integrated radiation treatment planning, delivery, and data management, enabling clinicians to deliver ultra-precise treatments to approximately 50 patients per day; iDMS data management system, a fully integrated treatment planning and data management systems; and Accuray precision treatment planning system, a treatment planning and data management systems. In addition, it offers post-contract customer support, installation, training, and other professional services. The company primarily markets its products directly to customers, including hospitals and stand-alone treatment facilities through its sales organization, as well as to customers through sales agents and group purchasing organizations in the United States; and to customers directly and through distributors and sales agents internationally. Accuray Incorporated was incorporated in 1990 and is headquartered in Madison, Wisconsin.
Read More

Today's Range

Now: $1.74
Low: $1.74
High: $1.92

50 Day Range

MA: $1.83
Low: $1.49
High: $2.34

2 Week Range

Now: $1.74
Low: $1.46
High: $4.30

Volume

374,262 shs

Average Volume

546,162 shs

Market Capitalization

$172.68 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.44